Japanese, Swiss Form Cambridge Biotech | Chemical & Engineering News
Volume 93 Issue 24 | p. 17 | Concentrates
Issue Date: June 15, 2015

Japanese, Swiss Form Cambridge Biotech

Department: Business
Keywords: automimmune disease, spin-offs

Japan’s Astellas Pharma and Switzerland’s Anokion are joining to create a new company, Kanyos Bio, based on technology from Anokion, a spin-off from Switzerland’s ETH Lausanne. Anokion has developed antigen-specific immune tolerance technology to reduce the immunogenicity of therapeutic proteins and treat autoimmune and allergic diseases. Kanyos will launch in Cambridge, Mass., with $16 million in financing and will target treatments for type 1 diabetes and celiac disease.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment